Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

1. FDA approved Alnylam's Amvuttra for treating ATTR-CM in adults. 2. Amvuttra is now the first FDA-approved therapy for ATTR-CM. 3. JPMorgan upgraded Alnylam, projecting a billion-dollar market for Amvuttra. 4. Analyst forecasts 2025 sales of $81 million for Amvuttra's cardiomyopathy indication. 5. ALNY stock rose 3.50% following positive developments and analyst upgrades.